Vertical: HealthcareBase Year: 201711 Sections
Market Size (2017)
$867.10M
Projected (2023)
$1.11B
CAGR (2015–2023)
4.2%
Key Players
10+
The global prils market includes active pharmaceutical ingredients (API). APIs are biologically active ingredients or substances which are an important part of any medicine. There are different APIs available with different properties and are used accordingly by the pharmaceutical, biotech, and nutritional industry to develop new products. The key factors responsible for driving the market are increasing prevalence of heart diseases, hypertension and kidney related problems, rising geriatric population, growing importance of generic drugs, and also the overall uptake of the biopharmaceuticals industry. Nevertheless, factors such as unfavorable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures hamper the market growth.
The Prils Market market is projected to grow at a CAGR of 4.2% from 2015 to 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe scope of the global prils market study includes the market size analysis and a detailed analysis of the manufacturers’ products and strategies. The market has been segmented based on type, application, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2016
Forecast Period
2018 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global prils market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share.
The vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.
Pfizer Inc. is a major player in the market. Pfizer, Inc. (Pfizer) is a leading research-based biopharmaceutical organization. Pfizer develops medicines and vaccines for a wide range of medical disciplines that include immunology, oncology, cardiology, diabetology/endocrinology, and neurology. It additionally teams up with healthcare providers, governments, and local communities to support and expand access to reliable and affordable healthcare around the world. It operates in countries such as Germany, France, Greece, Korea, Mexico, Russia, the Netherlands, India, Poland, Turkey, Israel, China, and others.
Market key developments give a glimpse of major events that have occurred and occurring in the market. The global prils market is developing, and players such as Aurobindo Pharma, Mylan N.V., Pfizer, Inc. are focusing on product launches and acquisition for improving their product portfolio and expanding their geographical reach. A company-wise detailed illustration of such events is mentioned in the below table.
Bargaining Power of Suppliers
The suppliers in the global prils industry are the developers and manufacturers of API molecules. Bargaining power of suppliers in the prils market is low to moderate. The number of suppliers in the market is high which gives plenty of options to drug manufacturers for material sourcing which is required for the production of various drugs, thus leaving suppliers with medium bargaining power. Switching cost of these suppliers is also high as suppliers tend to enter into long-term associations with the pharmaceutical manufacturers. However, the North American countries are consisting of a large number of suppliers which offer these molecules products at a relatively less price. Difficulties in manufacturing APIs such as peptides, sex hormones, and steroids give the bargaining power to suppliers. However, in the case of generic APIs, such thing is not applicable. Due to this reason of medium bargaining power of suppliers, the profit potential of the global prils industry gets condensed.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global prils market. The market has a large number of buyers comprising of various small and large molecules API manufacturing companies. The buyers of small molecule API globally are moderately inclined towards small molecule API manufacturers. Moreover, the buyers can exert moderate pressure on the manufacturers as they already provide high-quality products and services. Generic drugs offer a cost-effective alternative to drug innovators and significant savings to the customers. Biosimilars offer significant cost savings for insurance companies in India. Hence with the high level of products and services provided by the API manufacturers the bargaining power of suppliers tend to be moderate.
Threat of New Entrants
The threat of new entrants is moderate in the prils market. Any manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. The prils market is also characterized by a reasonable degree of brand loyalty where establishing a brand name is difficult for newcomers. Moreover, increasing geriatric population and funding are influencing many of the start-ups to take a keen interest in the field of research and development. The introduction of new drugs requires a clinical trial that demands long duration and huge capital investment. However, the cost involved in R&D is comparatively high which does not comfort the new entrants to enter the market easily.
Threat of Substitutes
The threat of substitutes in the prils market is moderate to high with the only substitute is in the form of large molecules. Buyer propensity to substitute is less due to the low availability of substitutes in this market. In addition, the high degree of switching cost minimizes the threat of substitutes. In addition to this, the introduction of generic drugs and increasing competition in the market has increased the availability of the products. Thus, the high degree of switching cost increases the threat of substitutes.
Intense Rivalry
The degree of competition in the prils market is moderate to high. The reserved degree of product differentiation among existing players increases the intensity of rivalry in the market. API manufacturing companies are trying to develop less expensive products to make these products more affordable in developing regions. To overcome the competition, players are engaged in developing a process to lower their manufacturing cost.
Moreover, the players are also developing advanced products for differentiating their brand from their rivals. Developing a new API molecule needs approval which is a time consuming and expensive process as the existing drugs are less effective and unsafe. However, the increasing government support and availability of funding have encouraged many new start-ups. To compete with multinational players, new and small companies are reducing the cost of their products.
Market estimates by geography (2023)
InsightNorth America leads with $377.10M by 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $48.00M | $53.20M | $59.10M | 2.6% | 5% |
| North America | $263.10M | $314.20M | $377.10M | 4.6% | 34% |
| Asia Pacific | $179.90M | $213.60M | $254.80M | 4.4% | 23% |
| Europe | $260.90M | $307.40M | $364.00M | 4.3% | 33% |
| South America | $46.00M | $51.30M | $57.20M | 2.8% | 5% |
| Total | $797.90M | $939.70M | $1.11B | 4.2% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$1.11B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Quinapril | $884.40M | 4.1% | 57% |
| Cilazapril | $304.80M | 4.6% | 20% |
| Ramipril | $242.50M | 4.5% | 16% |
| Benazepril | $114.60M | 4.4% | 7% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Prils Market covering market dynamics, competitive landscape, and strategic outlook.
The Prils Market market is projected to reach $1.11B by 2023, growing at 4.2% CAGR. The Quinapril segment holds the largest share.
The global prils market includes active pharmaceutical ingredients (APIs) ingredients. APIs are biologically active ingredients or substances which are important the part of any medicine. There are different APIs available with different properties, and they are used by pharmaceutical, biotech, and nutritional industries accordingly to develop new products. The key factors responsible for driving the market are increasing prevalence of heart diseases, hypertension and kidney related problems, rising geriatric population, growing importance of generic drugs, and also the overall uptake of the biopharmaceuticals industry.
However, factors such as unfavorable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures hamper the market growth.
The increasing prevalence of various chronic diseases has served as a good platform for manufacturers. Many types of active pharmaceutical ingredients are available in the market. However, many of them have different side-effects, and thus, there are a number of opportunities for manufacturers to develop new drugs. Many drugs are not prescribed to patients suffering from hypernatremia and other diseases. Beside this, there are huge opportunities for the development of the market in developing countries. Benazepril, cilazapril, quinapril, and ramipril are used for the treatment of heart-related diseases and hypertension.
Thus, the development of new drugs can pose tons of opportunities for the growth of the market.
There are different regulatory authorities such as the World Health Organization (WHO), the US Food and Drug Administration, and many more. These organizations have developed some guidelines which have to be followed by drug manufacturing companies. Regulatory compliance is considered to be the primary hurdle challenging the API market at every point. The FDA is regulating the quality assurance in the US and other regions.
Besides, Indian API manufacturers are investing in complying with the US FDA regulations for obtaining contracts from US-based companies. Although these regulations are serving to improve and maintain the quality of drugs, they are also curbing the growth of the API manufacturing market especially in developing regions of Asia-Pacific. These high regulations make the procedure more tedious and also increase the cost of production.
Pricing is among the most important factors for any product to withstand in the market. Pricing of any product or service depends on many factors which include the cost of raw material used for the product, technology used, cost of research and development, labor charges, and many other costs. Pricing plays an important role in the business to make key strategies. The API (active pharmaceutical ingredient) is a very broad range market and includes a variety of molecules with different chemical compositions having different properties. The cost of any API molecule depends on the money spent on research and development, type of technology used to manufacture, and maintenance of the product.
Active pharmaceutical ingredients are used by pharmaceutical, biotech, nutraceutical, and chemical companies to offer innovative products in the healthcare industry. Various generic manufacturers develop low grade as well as high-grade duloxetine API. Thus, the variation in price depends upon the purity of the product.
Active pharmaceutical ingredients (APIs) are pharmaceutical chemical compounds or mixture of substances used as an active ingredient. When the API or any active compound is used in any drug it has to be authorized from the regulatory agencies. There are different regulatory procedures adopted by different regions for filing of API as a proof of safety, efficacy and quality of the drug product. In US the filling of APIs is done according to the drug master file (DMF) and current good manufacturing practice regulations which is enforced by the US food and drug administration (FDA) regulations and, in Europe it is done according to the certification of suitability (CEP) and active substance master file (ASMF). Drug master file (DMF), are documents that covers all the confidential information about the raw material used, processes and technology used during processing, manufacturing, packaging and storing of drug which is submitted to the Food and Drug Administration (FDA).
Depending on the type of API Europe follows either of the procedure ASMF or CEP. Certification of suitability are applicable for active substances or excipients. CEP covers the information related to the quality of product, which can be used as a quality proof for the product. Whereas in the active substance master file (ASMF) procedure, which is also known as the European drug master file (EDMF) procedure, is only applicable to active substances. This document provides all the intellectual property rights to the manufacturer. However, these guidelines help to assures the standard quality, safety and efficacy of product.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 107 companies operating in the Prils Market market, including revenue, employee count, and market positioning where available.
Showing 107 of 107 companies
Company Headquarters: Basel, Switzerland Founded: 1996 Workforce: ~126,000 Company Working: Novartis AG (Novartis) was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its preceding companies have been known to develop innovative products which can be traced back to over 250 years. The company focuses on the development and marketing of products that contribute to human progress through advances in science and health. It provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory disease areas. Its Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, dermatology, central nervous system (CNS), gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas, among others. It also provides active pharmaceutical ingredients (API) and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.
Roche is the world's largest biotechnology company and the global leader in in-vitro diagnostics, and it is the only major healthcare group that operates both at scale under one roof. Founded in Basel in 1896, it generated CHF 61.5 billion of sales in 2025 across two divisions — Pharmaceuticals (CHF 47.7 billion) and Diagnostics (CHF 13.8 billion) — with a core operating margin of 35.5% and core EPS of CHF 19.46. Control rests with the founding Hoffmann and Oeri families, whose pooled voting block held 64.97% of the bearer shares at 31 December 2025, an ownership structure that underwrites an unusually long investment horizon: 39 consecutive dividend increases and CHF 12.2 billion of core R&D in 2025. Strategically, Roche is converting a legacy oncology franchise into a broader portfolio anchored in cancer, cardiovascular–metabolic disease (notably obesity) and neurology, while defending an installed diagnostics base against Chinese pricing reform and US trade and pricing policy. --- ### What the company does Roche discovers, develops, manufactures and commercialises prescription medicines and in-vitro diagnostic systems, assays and software. It is organised into two reporting divisions plus a Corporate centre. The Pharmaceuticals Division comprises Roche Pharmaceuticals (including the wholly owned US biotechnology business Genentech, based in South San Francisco) and Chugai Pharmaceutical of Japan, in which Roche Holding held 59.89% of issued shares and 61.12% of voting rights as of early 2025. The Diagnostics Division sells instruments, reagents, consumables and digital solutions to central laboratories, molecular laboratories, pathology laboratories and decentralised/near-patient settings, and includes Foundation Medicine (comprehensive genomic profiling), Ventana/Roche Tissue Diagnostics, Roche Diabetes Care and Roche Information Solutions. Roche's own framing, per its FY2025 corporate boilerplate, is that it was founded in 1896 as one of the first industrial manufacturers of branded medicines and has become the world's largest biotechnology company and the global leader in in-vitro diagnostics, pursuing personalised healthcare by combining pharmaceuticals, diagnostics and clinical-practice data insights. Its investor materials state that the two divisions jointly focus on three disease areas expected to account for almost 50% of the global disease burden by 2035: cancer, cardiovascular–metabolic disease and neurological disease. **Independent characterisation.** Roche is best understood as two structurally different businesses stapled together by a personalised-medicine thesis. Pharmaceuticals is a high-margin, patent-cliff-exposed innovation business: it earned a 49.2% core operating margin in 2025 on CHF 47.7 billion of sales and delivered CHF 19.5 billion of operating free cash flow, but its economics depend on replacing expiring franchises faster than biosimilars erode them. Diagnostics is a capital-intensive, razor-and-blade instrument-and-reagent business with far thinner economics — a 14.4% core operating margin in 2025, down 1.1 percentage points, and only CHF 0.7 billion of operating free cash flow on CHF 13.8 billion of sales after a 17% increase in capital expenditure. The strategic case for keeping them together (companion diagnostics, patient selection, real-world data) is real but has never been visible as a quantified margin premium in the segment disclosures. In practice, the Group's cash generation and valuation are driven overwhelmingly by Pharmaceuticals. ### Revenue model Roche reports "Revenue" of CHF 63,356m for 2025 (sales of CHF 61,516m plus other revenue of CHF 1,840m). There is no subscription line; the closest analogue is the recurring reagent and service annuity generated by the installed diagnostics instrument base, which Roche does not disclose separately. ### Value chain position, customers and end markets Roche is a fully integrated originator: it runs its own discovery organisations (pRED in Basel, gRED at Genentech, plus Chugai's independent research), its own late-stage development function under the Chief Medical Officer, its own biologics and device manufacturing network, and its own commercial affiliates in more than 100 countries. It supplements internal discovery with in-licensing and bolt-on M&A — CHF 4.8 billion of intangible assets were recognised in the Pharmaceuticals Division in 2025 from in-licensing, business combinations and asset acquisitions. Customers are payers and reimbursement authorities (the economic buyer in most markets), hospital systems and specialist prescribers, central and reference laboratories, pathology laboratories, blood-screening organisations, retail pharmacy and, increasingly in the US, direct-to-consumer channels via the TrumpRx platform. End markets by therapeutic area in Pharmaceuticals for 2025 were Oncology/Haematology 50.2% of divisional sales, Neurology 20.6%, Immunology 14.1%, Ophthalmology 8.8% and other areas 6.3%.
Company Overview Company Headquarters: Pennsylvania, US Founded: 1961 Workforce: 35,000+ Company Working: Mylan N.V. (Mylan) is a leading global pharmaceutical company. The company develops, licenses, manufactures, markets, and distributes generics, branded generics, brand name, and over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories. Its global portfolio constitutes more than 7,500 marketed generic and branded generic brand names and OTC products around the world covering a vast array of therapeutic categories. Mylan’s team works in various offices and manufacturing facilities across the world. It has global centers in Bangalore, India; Canonsburg, Pennsylvania; and Dublin, Ireland. Its global research and development (R&D) centers are situated in Hyderabad, India, and Morgantown, West Virginia. It also has 12 technology-focused R&D sites across Europe, India, Japan, and the US. It adheres to the highest quality standards across its 50 manufacturing facilities worldwide
Company Headquarters: Hyderabad, Andhra Pradesh Founded: 1986 Workforce: 5,001-10,000 Company Working: Aurobindo Pharma is a vertically integrated pharmaceutical company that delivers innovative solutions. The company manufactures and sells over 300 products in over 150 countries across the globe through six major therapeutic segments such as antibiotics, anti-retroviral, CVS, CNS, gastroenterological, and anti-allergic. Through cost-effective manufacturing capabilities and a few loyal customers, the company has entered into the high margin specialty generic formulations segment. Aurobindo Pharma has evolved into a knowledge-driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries.
Company Headquarters: Richmond, British Columbia (US) Founded: 2001 Workforce: 10 Company Working: Canagen Pharmaceuticals Inc. is a subsidiary of the Fazio Group of Companies. Canagen Pharmaceuticals Inc. is an innovative generic pharmaceuticals company involved in the manufacturing of generic pharmaceutical products, active pharmaceutical ingredients (API), and over-the-counter (OTC) medication. The company has its in-house research and development facility to develop and commercialize innovative drugs for the treatment of various critical diseases such as oncology, cardiovascular, dementia, and anti-viral infections. Canagen Pharmaceuticals Inc. has its pharmaceutical manufacturing factories in India, China, Canada, and Russia and sales and distribution offices in the US, India, China, Hong Kong, and Cyprus.
Company Headquarter: Mumbai, India Founded: 1968 Workforce: 15,000+ Company Working: Lupin is a global pharmaceutical company that deals in a wide range of products such as branded and generic formulations, biotechnology products, APIs, and specialty drugs. The company is a prominent player in the therapeutic segment such as gynecology, cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal (GI), anti-infective (AI), and non-steroidal anti-inflammatory drugs (NSAIDS). Also, it has a global leader in the fields of the anti-TB and Cephalosporin segment. Lupin has a presence in more than 100 countries. It has 18 manufacturing facilities, located in many parts of India, Japan, the US, Mexico, and Brazil. All these facilities are benchmarked to international standards to meet stringent quality standards. Also, these facilities are approved by international agencies such as the US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and the MCC South Africa.
12 interactive charts drawn from the Prils Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Prils Market South America Of South America
Global Prils Market Germany, Spain, France, United Kingdom, Italy and Rest Of Europe By Country
Global Prils Market Australia, China, India, Japan, South Korea and Rest Of Asia Pacific By Country
Global Prils Market United States and Canada Of North America By Country
Global Prils Market Middle East And Africa Of Middle East And Africa
Global Prils Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
